name: Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)


name: Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet


name: Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate


name: Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)


name: Needle insertion(s) without injection(s); 1 or 2 muscle(s)


name: Insertion of needle in 2 muscles without injection


name: Needle insertion(s) without injection(s); 3 or more muscles


name: Insertion of needle in 3 or more muscles


name: Manual preparation and insertion of drug-delivery device(s), deep (eg, subfascial) (List separately in addition to code for primary procedure)


name: Manual preparation and insertion of deep drug delivery device into muscle


name: Manual preparation and insertion of deep drug delivery devices into muscle


name: Removal of drug-delivery device(s), deep (eg, subfascial) (List separately in addition to code for primary procedure)


name: Removal of drug-delivery devices from beneath fibrous covering of muscle


name: Manual preparation and insertion of drug-delivery device(s), intramedullary (List separately in addition to code for primary procedure)


name: Manual preparation and insertion of intramedullary drug delivery device into bone


name: Manual preparation and insertion of intramedullary drug delivery devices into bone


name: Removal of drug-delivery device(s), intramedullary (List separately in addition to code for primary procedure)


name: Removal of drug-delivery devices from marrow cavity of bone


name: Removal of intramedullary drug delivery device from bone


name: Removal of intramedullary drug delivery devices from bone


name: Manual preparation and insertion of drug-delivery device(s), intra-articular (List separately in addition to code for primary procedure)


name: Manual preparation and insertion of intra-articular drug delivery device into joint


name: Manual preparation and insertion of intra-articular drug delivery devices into joint


name: Removal of drug-delivery device(s), intra-articular (List separately in addition to code for primary procedure)


name: Removal of drug-delivery devices into joint


name: Removal of intra-articular drug delivery device from joint


name: Removal of intra-articular drug delivery devices from joint


name: Excision of chest wall tumor involving rib(s), with plastic reconstruction; without mediastinal lymphadenectomy


name: Excision of neoplasm of chest wall including rib with plastic reconstruction


name: Excision of neoplasm of chest wall including ribs with plastic reconstruction


name: Excision of neoplasm of chest wall including ribs with plastic reconstruction and mediastinal lymphadenectomy


name: Nasal/sinus endoscopy, surgical, with orbital decompression


name: Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation)


name: Surgical endoscopy of nose and sinus with dilation of frontal sinus ostium


name: Surgical endoscopy of nose and sinus with dilation of sphenoid sinus ostium


name: Pericardiocentesis, including imaging guidance, when performed


name: Pericardiocentesis using imaging guidance


name: Pericardial drainage with insertion of indwelling catheter, percutaneous, including fluoroscopy and/or ultrasound guidance, when performed


name: Pericardial drainage with insertion of indwelling catheter, percutaneous, including fluoroscopy and/or ultrasound guidance, when performed; 6 years and older without congenital cardiac anomaly


name: Pericardial drainage with insertion of indwelling catheter, percutaneous, including fluoroscopy and/or ultrasound guidance, when performed; birth through 5 years of age or any age with congenital cardiac anomaly


name: Pericardial drainage with insertion of indwelling catheter, percutaneous, including CT guidance


name: Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when performed


name: Transcatheter removal of permanent leadless pacemaker from right ventricle using imaging guidance


name: Ascending aorta graft, with cardiopulmonary bypass, includes valve suspension, when performed


name: Ascending aorta graft, with cardiopulmonary bypass, includes valve suspension, when performed; for aortic dissection


name: Insertion of graft in ascending aorta for dissection of aorta with suspension of aortic valve, with cardiopulmonary bypass


name: Insertion of graft in ascending aorta for dissection of aorta with cardiopulmonary bypass


name: Ascending aorta graft, with cardiopulmonary bypass, includes valve suspension, when performed; for aortic disease other than dissection (eg, aneurysm)


name: Insertion of graft in ascending aorta for aneurysm, with cardiopulmonary bypass


name: Insertion of graft in ascending aorta for aneurysm, with suspension of aortic valve, with cardiopulmonary bypass


name: Insertion of graft in ascending aorta for disease of aorta other than dissection, with cardiopulmonary bypass


name: Transverse aortic arch graft, with cardiopulmonary bypass, with profound hypothermia, total circulatory arrest and isolated cerebral perfusion with reimplantation of arch vessel(s) (eg, island pedicle or individual arch vessel reimplantation)


name: Insertion of graft in transverse arch of aorta, with cardiopulmonary bypass, with profound hypothermia, total circulatory arrest, and isolated cerebral perfusion with individual reimplantation of arch vessels


name: Insertion of graft in transverse arch of aorta, with cardiopulmonary bypass, with profound hypothermia, total circulatory arrest, and isolated cerebral perfusion with island pedicle reimplantation of arch vessel


name: Insertion of graft in transverse arch of aorta, with cardiopulmonary bypass, with profound hypothermia, total circulatory arrest, and isolated cerebral perfusion with island pedicle reimplantation of arch vessels


name: Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for rupture or other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer, traumatic disruption), unilateral (List separately in addition to code for primary procedure)


name: Endovascular repair of iliac artery, not associated with placement of an aorto-iliac artery endograft at the same session, by deployment of an iliac branched endograft, including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer), unilateral


name: Exploration not followed by surgical repair, artery


name: Exploration not followed by surgical repair, artery; upper extremity (eg, axillary, brachial, radial, ulnar)


name: Exploration of artery of upper extremity


name: Exploration not followed by surgical repair, artery; lower extremity (eg, common femoral, deep femoral, superficial femoral, popliteal, tibial, peroneal)


name: Exploration of artery of lower extremity


name: Tying of single internal hemorrhoid group


name: Tying of multiple internal hemorrhoid groups


name: Hemorrhoidectomy, internal, by transanal hemorrhoidal dearterialization, 2 or more hemorrhoid columns/groups, including ultrasound guidance, with mucopexy, when performed


name: Internal hemorrhoidectomy by transanal dearterialization of multiple hemorrhoid columns using ultrasound guidance


name: Internal hemorrhoidectomy by transanal dearterialization of multiple hemorrhoid columns using ultrasound guidance, with mucopexy


name: Internal hemorrhoidectomy by transanal dearterialization of multiple hemorrhoid groups using ultrasound guidance


name: Internal hemorrhoidectomy by transanal dearterialization of multiple hemorrhoid groups using ultrasound guidance, with mucopexy


name: Preperitoneal pelvic packing for hemorrhage associated with pelvic trauma, including local exploration


name: Exploration and packing of wound in pelvic region


name: Preperitoneal pelvic packing for hemorrhage associated with pelvic trauma, with local exploration


name: Re-exploration of pelvic wound with removal of preperitoneal pelvic packing, including repacking, when performed


name: Re-exploration of pelvic wound with removal of preperitoneal pelvic packing


name: Re-exploration of pelvic wound with removal of preperitoneal pelvic packing and repacking


name: Spinal puncture, lumbar, diagnostic; with fluoroscopic or CT guidance


name: Diagnostic puncture of lumbar spine using fluoroscopic guidance


name: Spinal puncture, therapeutic, for drainage of cerebrospinal fluid (by needle or catheter); with fluoroscopic or CT guidance


name: Injection(s), anesthetic agent(s) and/or steroid


name: Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular)


name: Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve


name: Injection of anesthetic agent and steroid into greater occipital nerve


name: Injection of steroid into greater occipital nerve


name: Injection(s), anesthetic agent(s) and/or steroid; vagus nerve


name: Injection of anesthetic agent and/or steroid into vagus nerve


name: Injection of anesthetic agent and steroid into vagus nerve


name: Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed


name: Injection of anesthetic agent and steroid into brachial plexus


name: Injection of steroid into brachial plexus


name: Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed


name: Injection of anesthetic agent and/or steroid into upper arm and shoulder nerve (axillary nerve)


name: Injection of anesthetic agent and steroid into axillary nerve


name: Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve


name: Injection of anesthetic agent and/or steroid into suprascapular shoulder nerve


name: Injection of anesthetic agent and steroid into suprascapular nerve


name: Injection of steroid into suprascapular nerve


name: Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level


name: Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level (List separately in addition to code for primary procedure)


name: Injection of anesthetic agent and steroid into intercostal nerve, each additional level


name: Injection of anesthetic agent into intercostal nerve, each additional level


name: Injection of steroid into intercostal nerve, each additional level


name: Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves


name: Injection of anesthetic agent and steroid into ilioinguinal nerves


name: Injection of steroid into iliohypogastric and ilioinguinal nerves


name: Injection of steroid into iliohypogastric nerve


name: Injection of steroid into ilioinguinal nerve


name: Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve


name: Injection of anesthetic agent and steroid into pudendal nerve


name: Injection of steroid into pudendal nerve


name: Injection(s), anesthetic agent(s) and/or steroid; paracervical (uterine) nerve


name: Injection of anesthetic agent and steroid into paracervical nerve of uterus


name: Injection of steroid into paracervical nerve of uterus


name: Injection(s), anesthetic agent(s) and/or steroid; sciatic nerve, including imaging guidance, when performed


name: Injection of anesthetic agent and/or steroid into lower back and leg nerve (sciatic nerve)


name: Injection of anesthetic agent and steroid into sciatic nerve


name: Injection of anesthetic agent and steroid into femoral nerve


name: Injection of anesthetic agent and steroid into branch of peripheral nerve


name: Injection of anesthetic agent and steroid into peripheral nerve


name: Injection of anesthetic agent into branch of peripheral nerve


name: Injection of steroid into branch of peripheral nerve


name: Injection of steroid into peripheral nerve


name: Injection(s), anesthetic agent(s) and/or steroid; nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)


name: Injection of anesthetic agent and steroid into nerves innervating sacroiliac joint using fluoroscopic guidance


name: Injection of anesthetic agent into nerves innervating sacroiliac joint using fluoroscopic guidance


name: Injection of steroid into nerves innervating sacroiliac joint using fluoroscopic guidance


name: Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed


name: Injection of anesthetic agent and steroid into branches of genicular nerve


name: Injection of anesthetic agent and steroid into branches of genicular nerve using imaging guidance


name: Injection of anesthetic agent into branches of genicular nerve


name: Injection of anesthetic agent into branches of genicular nerve using imaging guidance


name: Injection of steroid into branches of genicular nerve


name: Injection of steroid into branches of genicular nerve using imaging guidance


name: Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed


name: Destruction by neurolytic agent of branches of genicular nerve


name: Destruction by neurolytic agent of branches of genicular nerve using imaging guidance


name: Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)


name: Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration with insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration with insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration with insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by manual technique with insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by manual technique with insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by manual technique with insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by manual technique with insertion of intraocular lens prosthesis, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by mechanical technique with insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by mechanical technique with insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by mechanical technique with insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by mechanical technique with insertion of intraocular lens prosthesis, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by phacoemulsification with insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by phacoemulsification with insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by phacoemulsification with insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by phacoemulsification with insertion of intraocular lens prosthesis, on patient in the amblyogenic developmental stage


name: Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with endoscopic cyclophotocoagulation


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by irrigation and aspiration, with endoscopic cyclophotocoagulation and insertion of intraocular lens, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by manual technique, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by manual technique, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis with suture support


name: Complex 1-stage extracapsular cataract removal by manual technique, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by manual technique, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis, with primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by phacoemulsification, with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis and iris expansion device


name: Complex 1-stage extracapsular cataract removal by phacoemulsification, with endoscopic cyclophotocoagulation and insertion of intraocular lens, on patient in the amblyogenic developmental stage


name: Complex 1-stage extracapsular cataract removal by phacoemulsification, with endoscopic cyclophotocoagulation with insertion of intraocular lens prosthesis and primary posterior capsulorrhexis


name: Complex 1-stage extracapsular cataract removal by phacoemulsification, with endoscopic cyclophotocoagulation with insertion of intraocular lens prosthesis with suture support


name: Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification)


name: 1-stage extracapsular cataract removal by irrigation and aspiration with insertion of intraocular lens prosthesis


name: 1-stage extracapsular cataract removal by mechanical technique with insertion of intraocular lens prosthesis


name: Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with endoscopic cyclophotocoagulation


name: 1-stage extracapsular cataract removal by irrigation and aspiration with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis


name: 1-stage extracapsular cataract removal by mechanical technique with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis


name: 1-stage extracapsular cataract removal by phacoemulsification with endoscopic cyclophotocoagulation and insertion of intraocular lens prosthesis


name: Complete acute abdomen x-ray series, erect and decubitus views, and anteroposterior chest view


name: Complete acute abdomen x-ray series, erect and decubitus views, and single chest view


name: Complete acute abdomen x-ray series, supine and decubitus views, and anteroposterior chest view


name: Complete acute abdomen x-ray series, supine and decubitus views, and single chest view


name: Complete acute abdomen x-ray series, supine and erect views, and anteroposterior chest view


name: Complete acute abdomen x-ray series, supine and erect views, and single chest view


name: Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed


name: Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; single-contrast (eg, barium) study


name: X-ray study of esophagus with barium, with scout x-ray of chest and delayed image


name: Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; double-contrast (eg, high-density barium and effervescent agent) study


name: X-ray study of esophagus with double contrast


name: X-ray study of esophagus with double contrast, with scout x-ray of chest and delayed image


name: X-ray study of esophagus with high-density barium and effervescent agent contrast


name: X-ray study of esophagus with high-density barium and effervescent agent contrast, with scout x-ray of chest and delayed image


name: Radiologic examination, swallowing function, with cineradiography/videoradiography, including scout neck radiograph(s) and delayed image(s), when performed, contrast (eg, barium) study


name: X-ray study of swallowing function with contrast, with cineradiography


name: Radiologic examination, upper gastrointestinal tract, including scout abdominal radiograph(s) and delayed image(s), when performed


name: Single contrast X-ray of upper digestive tract


name: X-ray of upper gastrointestinal tract with barium


name: X-ray of upper gastrointestinal tract with barium, with scout x-ray of abdomen and delayed image


name: X-ray of upper gastrointestinal tract with single contrast


name: X-ray of upper gastrointestinal tract with single contrast, with scout x-ray of abdomen and delayed image


name: Double contrast X-ray of upper digestive tract


name: X-ray of upper gastrointestinal tract with double contrast


name: X-ray of upper gastrointestinal tract with double contrast, with scout x-ray of abdomen and delayed image


name: X-ray of upper gastrointestinal tract with double contrast, with scout x-ray of abdomen and delayed image and administration of glucagon


name: X-ray of upper gastrointestinal tract with double contrast, with scout x-rays of abdomen and delayed images


name: X-ray of upper gastrointestinal tract with specific high density barium and effervescent agent contrast, with scout x-ray of abdomen and delayed image


name: Radiologic small intestine follow-through study, including multiple serial images (List separately in addition to code for primary procedure for upper GI radiologic examination)


name: Follow-through x-ray of small intestine with multiple serial images


name: Radiologic examination, small intestine, including multiple serial images and scout abdominal radiograph(s), when performed


name: Radiologic examination, small intestine, including multiple serial images and scout abdominal radiograph(s), when performed; single-contrast (eg, barium) study


name: X-ray of small intestine with single contrast, with multiple serial films


name: X-ray of small intestine with single contrast, with scout x-ray of abdomen and delayed image


name: X-ray of small intestine with double contrast and administration of glucagon


name: X-ray of small intestine with double contrast, with scout x-ray of abdomen and multiple serial films and administration of glucagon


name: X-ray of small intestine with high-density barium and air contrast administered via enteroclysis tube


name: X-ray of small intestine with high-density barium and air contrast administered via enteroclysis tube and administration of glucagon


name: X-ray of small intestine with high-density barium and air contrast administered via enteroclysis tube, with scout x-ray of abdomen and multiple serial films


name: X-ray of small intestine with high-density barium and air contrast administered via enteroclysis tube, with scout x-ray of abdomen and multiple serial films and administration of glucagon


name: Radiologic examination, colon, including scout abdominal radiograph(s) and delayed image(s), when performed


name: X-ray of colon with barium contrast, with scout x-ray of abdomen and delayed image


name: X-ray of colon with specific high density barium and air contrast


name: X-ray of colon with specific high density barium and air contrast, with scout x-ray of abdomen and delayed image


name: X-ray of colon with specific high density barium and air contrast, with administration of glucagon


name: X-ray of colon with specific high density barium and air contrast, with scout x-ray of abdomen and delayed image and administration of glucagon


name: Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan


name: Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed)


name: Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan


name: Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan


name: Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability)


name: Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan


name: Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed)


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); planar, single area (eg, head, neck, chest, pelvis), single day imaging


name: Planar imaging of distribution of radiopharmaceutical agent in chest, single day


name: Planar imaging of distribution of radiopharmaceutical agent in chest, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agent in head, single day


name: Planar imaging of distribution of radiopharmaceutical agent in head, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agent in limited area, single day


name: Planar imaging of distribution of radiopharmaceutical agent in limited area, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agents in neck, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agent in neck, single day


name: Planar imaging of distribution of radiopharmaceutical agent in pelvis, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agents in chest, single day


name: Planar imaging of distribution of radiopharmaceutical agents in chest, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agents in head, single day


name: Planar imaging of distribution of radiopharmaceutical agents in head, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agents in limited area, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agent in neck, with vascular flow and blood pool imaging, single day


name: Planar imaging of distribution of radiopharmaceutical agents in neck, single day


name: Planar imaging of distribution of radiopharmaceutical agents in pelvis, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in chest, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in chest, single day


name: Planar imaging radiopharmaceutical localization of inflammation in head, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in head, single day


name: Planar imaging radiopharmaceutical localization of inflammation in limited area, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in limited area, single day


name: Planar imaging radiopharmaceutical localization of inflammation in neck, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in neck, single day


name: Planar imaging radiopharmaceutical localization of inflammation in pelvis, with vascular flow and blood pool imaging, single day


name: Planar imaging radiopharmaceutical localization of inflammation in pelvis, single day


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); planar, 2 or more areas (eg, abdomen and pelvis, head and chest), 1 or more days imaging or single area imaging over 2 or more days


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); planar, whole body, single day imaging


name: Planar imaging distribution of radiopharmaceutical agent in entire body, single day


name: Planar imaging distribution of radiopharmaceutical agents, with vascular flow and blood pool imaging in entire body, single day


name: Planar imaging distribution of radiopharmaceutical agents in entire body, single day


name: Planar imaging distribution of radiopharmaceutical agent, with vascular flow and blood pool imaging in entire body, single day


name: Planar imaging radiopharmaceutical localization of inflammation in entire body, single day


name: Planar imaging radiopharmaceutical localization of inflammation, with vascular flow and blood pool imaging in entire body, single day


name: Planar imaging distribution of radiopharmaceutical agent in entire body, multiple days


name: Planar imaging distribution of radiopharmaceutical agents in entire body, multiple days


name: Planar imaging distribution of radiopharmaceutical agent in entire body, with vascular flow and blood pool imaging, multiple days


name: Planar radiopharmaceutical localization of inflammation in entire body with vascular flow and blood pool imaging, multiple days


name: Planar radiopharmaceutical localization of inflammation in entire body, multiple days


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, single area (eg, head, neck, chest, pelvis) or acquisition, single day imaging


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT), minimum 2 areas (eg, pelvis and knees, chest and abdomen) or separate acquisitions (eg, lung ventilation and perfusion), single day imaging, or single area or acquisition over 2 or more days


name: Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen) or separate acquisitions (eg, lung ventilation and perfusion), single day imaging, or single area or acquisition over 2 or more days


name: Radiopharmaceutical quantification measurement(s) single area (List separately in addition to code for primary procedure)


name: Radiopharmaceutical quantification measurement of single area


name: Drug test(s), presumptive, any number of drug classes, any number of devices or procedures


name: Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities


name: Cytogenomic neoplasia (genome-wide) microarray analysis wih interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities


name: PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis


name: PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence


name: Gene analysis (partner and localizer of BRCA2) full sequence analysis


name: Partner and localizer of BRCA2 (PALB2) full gene sequence analysis


name: PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant


name: Gene analysis (partner and localizer of BRCA2) for detection of known familial variant


name: Partner and localizer of BRCA2 (PALB2) gene analysis for detection of known familial variant


name: PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)


name: Gene analysis (partner and localizer of BRCA2) targeted sequence analysis


name: Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PIK3CA) targeted gene sequence analysis


name: Gene analysis (UDP glucuronosyltransferase 1 family, polypeptide A1) for detection of common variants


name: Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score


name: mRNA gene expression analysis of 12 genes in breast tumor tissue


name: Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score


name: mRNA gene expression analysis of 22 genes in prostate tumor tissue


name: mRNA gene expression analysis of 15 genes in eye melanoma o tissue or fine needle aspirate


name: Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique


name: Detection of Mycoplasma genitalium by DNA or RNA probe


name: Detection of Mycoplasma genitalium by amplified DNA probe technique


name: Detection of Mycoplasma genitalium by amplified RNA probe technique


name: IgG and IgM analysis of 80 biomarkers of systemic lupus erythematosus in serum


name: IgG and IgM analysis of 80 biomarkers for systemic lupus erythematosus in serum, algorithm reported with a risk score


name: Testing for amines associated with autism spectrum disorder in plasma


name: Measurement of placental alpha-micro globulin-1 (PAMG-1) in cervical/vaginal fluid to evaluate risk of premature rupture of membranes


name: Protein expression profiling of 4 biomarkers of breast cancer in precancerous breast tissue


name: Protein expression profiling of 4 biomarkers for breast cancer (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score


name: Detection of Candida species by amplified probe


name: Detection of Candida albicans, Candida glabrata, Candida parapsilosis, Candida kruseii, Candida tropicalis, and Candida auris using amplified probe technique with qualitative report of the presence or absence of each species


name: mRNA expression profiling of miR-31-3 in colon tumor tissue


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) for common and select rare variants


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) full sequence analysis


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) full gene sequence analysis


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted sequence analysis for CYP2D6-2D7 hybrid gene


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted sequence analysis for CYP2D6-2D6 hybrid gene


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted sequence analysis for non-duplicated gene when duplication/multiplication is trans


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted sequence analysis for 5 gene duplication/multiplication


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 3' gene duplication/multiplication analysis of targeted sequence


name: Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted sequence analysis for 3 gene duplication/multiplication


name: Detection of Immunoglobulin paraprotein (M-protein) in blood or urine


name: Detection of immunoglobulin paraprotein (M-protein), including isotype, by immunoprecipitation and mass spectrometry in blood


name: Detection of immunoglobulin paraprotein (M-protein), including isotype, by immunoprecipitation and mass spectrometry in urine


name: Gene analysis of 16 genes to evaluate risk of opioid-use disorder


name: DNA analysis of urine and cheek swabs for specimen identity verification


name: Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), in urine and buccal swab, for specimen identity verification


name: Analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130 in plasma, with clinical risk factors, to evaluate probability of lung cancer


name: Definitive drug testing for 90 or more drugs in urine


name: Evaluation of response to chemotherapy drugs using motility contrast tomography of fresh or frozen tissue


name: Evaluation of response to chemotherapy drugs using motility contrast tomography of fresh tissue, reported as likelihood of sensitivity or resistance


name: Evaluation of response to chemotherapy drugs using motility contrast tomography of frozen tissue, reported as likelihood of sensitivity or resistance


name: Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens


name: Red blood cell (RBC) antigen DNA genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens


name: Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)


name: Evaluation of biomarker antibodies for inflammatory bowel disease


name: Enzyme-linked immunosorbent assay (ELISA) for cytolethal distending toxin B (CdtB) and vinculin IgG antibodies


name: Immunoassay for cytolethal distending toxin B (CdtB) and vinculin IgG antibodies


name: Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility


name: FISH identification of organisms in blood culture


name: Identification of bacteria and fungi in blood culture by rRNA fluorescence in situ hybridization (FISH), 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility


name: Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score


name: mRNA gene expression profiling of genes in heart transplant biopsy tissue to evaluate risk of rejection


name: mRNA gene expression profiling by microarray of 1283 genes in heart transplant biopsy tissue, algorithm reported as probability score for allograft rejection and injury


name: Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection


name: mRNA gene expression profiling of genes in kidney transplant tissue to evaluate risk of rejection


name: Microarray gene expression profiling of 1494 genes in allograft kidney transplant biopsy tissue, algorithm reported as a probability score for rejection


name: Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)


name: Gene expression profiling of melanoma in superficial sample collected by adhesive patch


name: Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)


name: mRNA gene expression profiling of 23 genes in skin melanoma tissue sample


name: Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result


name: Colorectal cancer screening by enumeration of tumor cells in blood


name: Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy


name: Measurement of 3 protein biomarkers for lung cancer in plasma


name: Immunoassay of 3 protein biomarkers for lung cancer in plasma using magnetic nanosensor technology, algorithm reported as risk score for likelihood of malignancy


name: Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected


name: Prescription drug monitoring for 65 common drugs in urine


name: Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis


name: Rapid sequence analysis of genome for unexplained constitutional disorder


name: Rapid sequence analysis of genome for unexplained heritable disorder


name: Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis


name: Test for markers of eosinophilic inflammation of esophagus


name: Test for detection of high-risk human papillomavirus in male urine


name: Detection of human papillomavirus (HPV), high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) in male urine


name: Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])


name: Gene sequence analysis panel of 15 genes associated with hereditary colon cancer and related disorders


name: Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])


name: Gene sequence analysis panel of 17 genes associated with hereditary breast cancer and related disorders


name: Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])


name: Gene sequence analysis panel of 24 genes associated with hereditary ovarian cancer and related disorders


name: Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)


name: Measurement of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in plasma to evaluate risk of rapid kidney function decline


name: Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion


name: Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method


name: Antigen test for detection of Clostridium difficile toxin in stool


name: Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer


name: Computer-assisted digital imaging of esophagus specimen slides to evaluate risk of cancer


name: Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species


name: DNA test for detection of 4 Aspergillus species


name: Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected


name: Monitoring of anti-cancer drugs in patient blood, serum, or plasma


name: Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis, utilizing formalin-fixed paraffin-embedded tissue


name: Gene analysis (KRAS and NRAS) in prostate tumor tissue


name: Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene


name: Gene analysis for detection of infectious agent and drug resistance gene


name: Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score


name: Measurement of PCA3 gene in urine and prostate-specific antigen (PSA) in serum to evaluate risk of prostate cancer


name: Measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score


name: Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus


name: Gene analysis (VIM and CCNA1 methylation) in esophageal cells to evaluate likelihood of precancerous changes


name: Vimentin (VIM) and Cyclin A1 (CCNA1) methylation analysis of esophageal cells, algorithm reported as likelihood for Barrett's esophagus


name: Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected


name: Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets


name: Detection of respiratory infectious agent by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected


name: Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications


name: Analysis of 35 or more drugs in mouth fluid to evaluate risk of prescription drug interactions


name: Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain


name: Analysis of 11 biochemical substances in urine to evaluate likelihood of atypical biochemical function associated with pain


name: Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA


name: Measurement of transplant donor cell-free DNA in transplant recipient plasma


name: Quantification of transplant donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in total cell-free DNA


name: Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events


name: Measurement of ceramides for assessment of heart disease risk


name: Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter


name: mRNA, gene expression profiling of 58 genes in tissue sample for B-cell lymphoma classification


name: B-cell lymphoma classification, mRNA gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes) in formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter


name: Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood


name: Blood test for sickle cells using VCAM-1


name: Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood


name: Blood test for sickle cells using P-Selectin


name: P-Selectin microfluidic flow adhesion test in whole blood for sickle cell disease


name: Mechanical fragility, RBC, shear stress and spectral analysis profiling


name: Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)


name: Gene analysis of genes associated with hereditary breast cancer and related disorders for gene sequence and duplication or deletion variants


name: Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of genes associated with hereditary colon cancer and related disorders


name: Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of 13 genes associated with hereditary breast cancer and related disorders


name: Hereditary breast cancer-related disorders targeted mRNA sequence analysis panel including 13 genes


name: Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of 17 genes associated with hereditary ovarian cancer and related disorders


name: Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of 11 genes associated with hereditary prostate cancer and related disorders


name: Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of 18 genes associated with hereditary pan cancer


name: Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)


name: Targeted mRNA sequence analysis of 12 genes associated with hereditary gynecological cancer


name: ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)


name: mRNA gene analysis (ataxia telangiectasia mutated)


name: Ataxia telangiectasia mutated (ATM) mRNA sequence analysis


name: PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)


name: mRNA gene analysis (partner and localizer of BRCA2)


name: BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)


name: mRNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair associated)


name: Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use


name: Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use


name: Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed


name: Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician or other qualified health care professional contact with the patient


name: Biofeedback training for bowel or bladder control, initial 15 minutes


name: Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately in addition to code for primary procedure)


name: Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral


name: Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report


name: Bilateral extended ophthalmoscopy with drawing of retina and depression of sclera for evaluation of peripheral retina, with interpretation and report


name: Unilateral extended ophthalmoscopy with drawing of retina and depression of sclera for evaluation of peripheral retina, with interpretation and report


name: Ophthalmoscopy, extended; with drawing of optic nerve or macula (eg, for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or bilateral


name: Bilateral extended ophthalmoscopy with drawing of optic macula, with interpretation and report


name: Unilateral extended ophthalmoscopy with drawing of macula, with interpretation and report


name: Unilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report


name: Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)


name: Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s)


name: Evaluation of auditory function for surgically implanted device candidacy, first hour


name: Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)


name: Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics


name: Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer


name: Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; recording only


name: Recording only of ambulatory blood pressure monitoring for 24 hours or longer


name: Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; scanning analysis with report


name: Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; review with interpretation and report


name: Review of ambulatory blood pressure monitoring for 24 hours or longer, with interpretation and report


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete bilateral study


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete unilateral study


name: Electroencephalogram (EEG) continuous recording, with video when performed, setup, patient education, and takedown when performed, administered in person by EEG technologist, minimum of 8 channels


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; unmonitored


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; with intermittent monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; with intermittent monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; unmonitored


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; with intermittent monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; with intermittent monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, with video (VEEG)


name: Health behavior assessment, or re-assessment (ie, health-focused clinical interview, behavioral observations, clinical decision making)


name: Health behavior intervention, individual, face-to-face


name: Health behavior intervention, individual, face-to-face; initial 30 minutes


name: Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face individual health behavior intervention, each additional 15 minutes


name: Health behavior intervention, group (2 or more patients), face-to-face


name: Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes


name: Face-to-face group health behavior intervention, initial 30 minutes


name: Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face group health behavior intervention, each additional 15 minutes


name: Health behavior intervention, family (with the patient present), face-to-face


name: Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes


name: Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face family (with patient present) health behavior intervention, each additional 15 minutes


name: Health behavior intervention, family (without the patient present), face-to-face


name: Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes


name: Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face family (without patient present) health behavior intervention, each additional 15 minutes


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes


name: Therapeutic interventions that focus on cognitive function and compensatory strategies to manage the performance of an activity, direct (one-on-one) patient contact, initial 15 minutes


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Therapeutic interventions that focus on cognitive function and compensatory strategies to manage the performance of an activity, direct (one-on-one) patient contact, each additional 15 minutes


name: Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes


name: Self-measured blood pressure using a device validated for clinical accuracy


name: Self-measured blood pressure using a device validated for clinical accuracy; patient education/training and device calibration


name: Self-measured blood pressure using a device validated for clinical accuracy; separate self-measurements of two readings one minute apart, twice daily over a 30-day period (minimum of 12 readings), collection of data reported by the patient and/or caregiver to the physician or other qualified health care professional, with report of average systolic and diastolic pressures and subsequent communication of a treatment plan to the patient


name: Self measured blood pressure measurements


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes


name: Online digital evaluation and management service, for established patient, for up to 7 days, cumulative time 5-10 minutes


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes


name: Online digital evaluation and management service, for established patient, for up to 7 days, cumulative time 21 or more minutes


name: Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month


name: Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure)


name: Remote physiologic monitoring treatment management services, health care professional time in calendar month requiring interactive communication with the patient/caregiver, each additional 20 minutes


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)


name: 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed


name: 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)


name: Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed


name: Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed; without evidence of retinopathy (DM)


name: Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae


name: Repair of valve between upper left and lower left chambers of heart (mitral valve) with insertion of artificial supporting tendons, accessed through apex of heart


name: Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture


name: Reconstruction of junction between upper left and lower left chambers of heart (annulus of mitral valve) with implantation of adjustable reconstruction device, via catheter, accessed through skin


name: Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach


name: Reconstruction of junction between upper right and lower right chambers of heart (annulus of tricuspid valve) with implantation of adjustable reconstruction device, via catheter, accessed through skin


name: Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report


name: Radiofrequency spectroscopy evaluation of surgical margins during partial mastectomy, with report


name: Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score


name: Bone material quality testing by microindentations of shin bone


name: Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance


name: Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance


name: Periurethral transperineal adjustable balloon continence device; removal, each balloon


name: Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume


name: Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional


name: Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Insertion of implant connecting groin artery and groin vein, with radiological supervision and interpretation and imaging guidance, via catheter, accessed through skin


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone-mineral density, interpretation and report


name: Bone strength and fracture risk assessment: retrieval and transmission of CT scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data


name: Bone strength and fracture risk assessment: retrieval and transmission of CT scan data only


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone-mineral density


name: Bone strength and fracture risk assessment: assessment of bone strength and fracture risk and bone mineral density


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; interpretation and report


name: Bone strength and fracture risk assessment: interpretation and report


name: Computed tomography scan taken for the purpose of biomechanical computed tomography analysis


name: CT scan for biomechanical computed tomography analysis


name: Anatomic model 3D-printed from image data set(s)


name: Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure


name: 3-D printed anatomic model; first individually prepared and processed component of anatomic structure


name: Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)


name: 3-D printed anatomic model; each additional individually prepared and processed component of anatomic structure


name: Anatomic guide 3D-printed and designed from image data set(s)


name: Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide


name: Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)


name: 3-D printed anatomic guide; each additional guide


name: Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral


name: Evacuation of meibomian tear glands of eyelids of both eyes


name: Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations


name: Evaluation of toxicity of chemotherapy drugs on cancer stem cells


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation


name: Harvesting of fatty tissue and creation of cellular implant for treatment of osteoarthritis


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral


name: Injection of fatty tissue cellular implant for treatment of osteoarthritis in knee, using ultrasound guidance


name: Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound


name: Blockage of fallopian tubes with implants inserted through cervix


name: Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound


name: Introduction of saline and air into fallopian tubes to test for blockage


name: transcatheter tricuspid valve repair, percutaneous approach


name: Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis


name: Repair of valve between upper right and lower right chambers of heart (tricuspid valve) using prosthesis delivered via catheter, accessed through skin; initial prosthesis


name: Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)


name: Repair of valve between upper right and lower right chambers of heart (tricuspid valve) using prosthesis delivered via catheter, accessed through skin; each additional prosthesis


name: Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed


name: Insertion or replacement of implantable cardioverter-defibrillator system with electrodes under breastbone


name: Insertion of substernal implantable defibrillator electrode


name: Insertion of implantable defibrillator electrode under breastbone


name: Removal of substernal implantable defibrillator electrode


name: Removal of implantable defibrillator electrode from under breastbone


name: Repositioning of previously implanted substernal implantable defibrillator-pacing electrode


name: Repositioning of previously implanted defibrillator electrode under breastbone


name: Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional


name: In-person programming device evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter


name: In-person interrogation device evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Electrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)


name: Electrophysiological evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional


name: Remote interrogation device evaluation of implantable cardioverter-defibrillator system with lead under breastbone, with analysis, review and report by healthcare professional


name: Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results


name: Remote interrogation device evaluation of implantable cardioverter-defibrillator system with lead under breastbone, with remote data acquisitions, receipt of transmissions and technician review, technical support and distribution of results


name: Removal of substernal implantable defibrillator pulse generator only


name: Removal of implantable defibrillator pulse generator from under breastbone


name: Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral


name: Freezing destruction of malignant breast tumors in one breast, accessed through skin


name: Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance


name: High-energy water vapor heat destruction of malignant prostate tissue, including imaging and needle guidance


name: Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia


name: Insertion of ventilating tube in eardrum using an automated tube delivery system under local anesthesia


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous


name: Transplantation of insulin-producing cells, via catheter accessed through skin using imaging guidance


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic


name: Transplantation of insulin-producing cells using endoscope inserted through wall of abdomen


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open


name: Transplantation of insulin-producing cells, open procedure


name: Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve


name: Implantation of nerve-stimulating device in posterior tibial nerve, accessed through skin


name: Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve


name: Revision or removal of nerve-stimulating device in posterior tibial nerve


name: Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters


name: Electronic analysis with simple programming of nerve-stimulating device in posterior tibial nerve


name: Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters


name: Electronic analysis with complex programming of nerve-stimulating device in posterior tibial nerve


name: face-to-face health and well-being coaching


name: Health and well-being coaching face-to-face; individual, initial assessment


name: Health and well-being coaching face-to-face; individual, follow-up session, at least 30 minutes


name: Health and well-being coaching face-to-face; group (2 or more individuals), at least 30 minutes


name: Face-to-face health and well-being coaching of group, at least 30 minutes


name: Multianalyte Assays with Algorithmic Analyses and Proprietary Laboratory Analyses


name: Immobilized Metal Affinity Chromatography


name: Stable Isotope Labeling with Amino Acids in Cell Culture


name: Chemokine (C-C Motif) Ligand 20 Measurement


name: Montreal Cognitive Assessment Naming Test


name: Chemokine (C-X-C Motif) Ligand 11 Measurement


name: Unspecified Cells to Leukocytes Ratio Measurement


name: Montreal Cognitive Assessment Orientation Test


name: CDISC SDTM Implementation Guide Version 3.2


name: CDISC SDTM Implementation Guide Version 3.3


name: Urinary System Findings Completion Status


name: Human Immunodeficiency Virus Measurement


name: Caregiver Oncology Needs Evaluation Tool


name: Chemokine (C-X3-C Motif) Ligand 1 Measurement


name: Erythrocyte Inclusion Bodies Measurement


name: Stereotactic Accelerated Partial Breast Irradiation


name: Montreal Cognitive Assessment Abstraction Test


name: Adjacent Tissue Transfer or Rearrangement


name: Mental health screening report:Find:Pt:^Patient:Doc


name: Guidance for percutaneous biopsy of Liver


name: PhenX - complete blood count protocol 220501:-:Pt:^Patient:-:PhenX


name: PhenX - complete blood count protocol 220501


name: {1 (0.1 ML) (diazepam 100 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 10 MG Dose Kit]


name: {2 (0.1 ML) (diazepam 100 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 20 MG Dose Kit]


name: Somatic symptom disorder score:Score:Pt:^Patient:Qn


name: Somatic symptom disorder screening report:Find:Pt:^Patient:Doc


name: Somatic symptom disorder screening report


name: Appointment of legal guardian:Find:Pt:^Patient:Nom


name: ADHD question consistency score:Score:Pt:^Patient:Qn


name: Megalencephaly Cutis Marmorata Telangiectatica Congenita (test kit)


name: Measured weight loss (observable entity)


name: Growth hormone receptor antagonist (disposition)


name: Accessibility of home entrance:Find:Pt:^Patient:Nom


name: Accessibility of home interior:Find:Pt:^Patient:Nom


name: Non-specific active suicidal thoughts:Find:Lifetime:^Patient:Ord


name: WellRx Questionnaire - revised:-:Pt:^Patient:-:WellRx


name: CD19 blasts/100 blasts in blood (lab test)


name: CT Guidance for injection of Joint space


name: CT Guidance for drainage and placement of drainage catheter of appendix


name: MR Guidance for stereotactic biopsy of Brain


name: Substance with acetylcholinesterase reactivator mechanism of action (substance)


name: Product containing vasopressin receptor agonist (product)


name: Vasopressin receptor agonist (disposition)


name: Product containing smoothened receptor agonist (product)


name: Smoothened receptor agonist (disposition)


name: Substance with sodium-hydrogen exchanger isoform 3 transporter inhibitor mechanism of action (substance)


name: Guidance for kyphoplasty of Lumbar spine


name: ADHD hyperactive symptoms severity:Imp:Pt:^Patient:Ord


name: ADHD inattentive symptoms severity:Imp:Pt:^Patient:Ord


name: Advance directive document format:Find:Pt:^Patient:Nom


name: Wish to be dead:Find:Lifetime:^Patient:Ord


name: CT Guidance for drainage and placement of drainage catheter of pancreas


name: CD127 blasts/100 blasts in blood (lab test)


name: Drug classes of medications taken:Type:Pt:^Patient:Nom


name: Genetic risk score for coronary heart disease:Score:Lifetime:^Patient:Qn


name: Home accessibility modification date:Date:Pt:^Patient:Qn


name: CT Guidance for drainage and placement of drainage catheter of subphrenic space


name: Dermatan sulfate & heparan sulfate & keratan sulfate panel


name: Dermatan sulfate & heparan sulfate & keratan sulfate panel:-:Pt:Ser/Plas:-


name: little c Ag^during infancy:PrThr:Pt:RBC:Ord


name: HEDIS 2020 Value Set - Mammography:-:Pt:^Patient:-


name: Total parenteral nutrition agent (substance)


name: Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel:-:Pt:^Patient:-


name: Comparison with previous results:Find:Pt:^Patient:Doc


name: PhenX - bone age protocol 220301:-:Pt:^Patient:-:PhenX


name: Body disposition facility name:ID:Pt:Facility:Nom


name: CD11c+CD19+ cells/100 cells in bone marrow


name: cytoplasmic CD22 blasts/100 blasts in blood


name: cytoplasmic CD13 blasts/100 blasts in blood


name: Sodium-hydrogen exchanger isoform 3 transporter inhibitor (disposition)


name: {28 (tolvaptan 15 MG Oral Tablet [Jynarque]) / 28 (tolvaptan 30 MG Oral Tablet [Jynarque]) } Pack [Jynarque 30/15 Carton]


name: {56 (tolvaptan 15 MG Oral Tablet [Jynarque]) } Pack [Jynarque 15/15 Carton]


name: CD11c+CD19+ cells/100 cells in cerebral spinal fluid


name: E Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: little e Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: Substance use disorder screening report:Find:Pt:^Patient:Doc


name: Cause of sick feeling:Find:Pt:^Patient:Nom


name: CD11c+CD19+ cells/100 cells in body fluid


name: CD11c+CD19+ cells/100 cells in tissue (lab test)


name: CD123 blasts/100 blasts in blood (lab test)


name: Best thing about your day:Find:Pt:^Patient:Nom


name: Body disposition facility address:Addr:Pt:Facility:Nom


name: Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel


name: Date and time of obstetric delivery:TmStp:Pt:^Patient:Qn


name: Date of most lethal suicide attempt:Date:Pt:^Patient:Qn


name: Date of most recent suicide attempt:Date:Pt:^Patient:Qn


name: CD14 blasts/100 blasts in blood (lab test)


name: CD16 blasts/100 blasts in blood (lab test)


name: CD1a blasts/100 blasts in blood (lab test)


name: Central alpha-2 adrenergic receptor agonist (disposition)


name: Substance with central alpha-2 adrenergic receptor agonist mechanism of action (substance)


name: little c Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: C Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: C Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: little c Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: DPYD gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: little e Ag^during infancy:PrThr:Pt:RBC:Ord


name: E Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: little e Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: CT Guidance for drainage and placement of drainage catheter of abdomen


name: CT Guidance for drainage and placement of drainage catheter of anus


name: CT Guidance for drainage and placement of drainage catheter of biliary ducts and gallbladder


name: CT Guidance for drainage and placement of drainage catheter of chest


name: CT Guidance for drainage and placement of drainage catheter of gallbladder


name: CT Guidance for drainage and placement of drainage catheter of kidney


name: CT Guidance for drainage and placement of drainage catheter of liver


name: CT Guidance for drainage and placement of drainage catheter of pelvis


name: CT Guidance for drainage and placement of drainage catheter of retroperitoneum


name: CT Guidance for exchange of nephrostomy tube of Kidney


name: CT guidance for fluid aspiration of breast


name: CT guidance for fluid aspiration of cervical spine intervertebral disc


name: CT guidance for fluid aspiration of chest


name: CT guidance for fluid aspiration of liver


name: CT guidance for fluid aspiration of lung


name: CT guidance for fluid aspiration of neck


name: CT guidance for fluid aspiration of pancreas


name: CT guidance for fluid aspiration of pleural space


name: CT Guidance for injection of Cervical spine Intervertebral disc


name: CT Guidance for localization of placenta of Uterus


name: CT guidance for needle localization of breast


name: CT guidance for needle localization of cervical spine


name: CT Guidance for needle localization of Lumbar spine


name: CT Guidance for needle localization of Thoracic spine


name: CT Guidance for percutaneous replacement of drainage tube of Abdomen


name: CT Guidance for percutaneous replacement of drainage tube of Pelvis


name: CT Guidance for percutaneous vertebroplasty of Lumbar spine


name: CT Guidance for percutaneous vertebroplasty of Thoracic spine


name: CT Guidance for placement of nephrostomy tube in Kidney


name: cytoplasmic CD179a blasts/100 blasts in blood